Trial Profile
A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 256066 (Primary) ; Azelastine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 12 Aug 2009 Actual patient number (70) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date (Feb 2008) added as reported by ClinicalTrials.gov.
- 19 Mar 2008 New trial record.